NO20082524L - Biologisk materiale og anvendelse av samme - Google Patents

Biologisk materiale og anvendelse av samme

Info

Publication number
NO20082524L
NO20082524L NO20082524A NO20082524A NO20082524L NO 20082524 L NO20082524 L NO 20082524L NO 20082524 A NO20082524 A NO 20082524A NO 20082524 A NO20082524 A NO 20082524A NO 20082524 L NO20082524 L NO 20082524L
Authority
NO
Norway
Prior art keywords
same
biological material
binding
surface antigen
cell surface
Prior art date
Application number
NO20082524A
Other languages
English (en)
Other versions
NO341192B1 (no
Inventor
Bjorn Frendeus
Original Assignee
Bioinvent Int Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioinvent Int Ab filed Critical Bioinvent Int Ab
Publication of NO20082524L publication Critical patent/NO20082524L/no
Publication of NO341192B1 publication Critical patent/NO341192B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2821—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against ICAM molecules, e.g. CD50, CD54, CD102
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Sammendrag: Bindingsmolekyl, inkludert antistoffmolekyl som bindes selektivt til et celleoverflateantigen på en target celle, og hvor bindingsmolekylene ved binding av celleoverflate-antigenet induserer apoptose i target cellen. Det er også framskaffet framgangsmåter og farmasøytiske blandinger for induksjon av apoptose samt anvendelser av samme.
NO20082524A 2005-12-12 2008-06-02 Apoptose-induserende anti-ICAM antistoff NO341192B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0525214A GB0525214D0 (en) 2005-12-12 2005-12-12 Biological materials and uses thereof
PCT/EP2006/012065 WO2007068485A2 (en) 2005-12-12 2006-12-08 Biological materials and uses thereof

Publications (2)

Publication Number Publication Date
NO20082524L true NO20082524L (no) 2008-09-09
NO341192B1 NO341192B1 (no) 2017-09-11

Family

ID=35735917

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20082524A NO341192B1 (no) 2005-12-12 2008-06-02 Apoptose-induserende anti-ICAM antistoff

Country Status (24)

Country Link
US (3) US7943744B2 (no)
EP (2) EP2468775A1 (no)
JP (3) JP5247463B2 (no)
KR (3) KR20140031402A (no)
CN (2) CN102517252A (no)
AU (1) AU2006326267B2 (no)
BR (1) BRPI0619741A2 (no)
CA (1) CA2632983C (no)
DK (1) DK1960432T3 (no)
ES (1) ES2577290T3 (no)
GB (1) GB0525214D0 (no)
HK (1) HK1121767A1 (no)
HU (1) HUE028363T2 (no)
IL (1) IL191868A (no)
MY (1) MY147438A (no)
NO (1) NO341192B1 (no)
NZ (2) NZ595644A (no)
PL (1) PL1960432T3 (no)
PT (1) PT1960432T (no)
RU (1) RU2432363C9 (no)
SI (1) SI1960432T1 (no)
UA (1) UA100664C2 (no)
WO (1) WO2007068485A2 (no)
ZA (1) ZA200804864B (no)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0525214D0 (en) * 2005-12-12 2006-01-18 Bioinvent Int Ab Biological materials and uses thereof
US20100041874A1 (en) * 2006-10-03 2010-02-18 Genmab A/S High throughput methods for characterization of antibodies
GB0903151D0 (en) * 2009-02-25 2009-04-08 Bioinvent Int Ab Antibody uses and methods
WO2011053763A2 (en) * 2009-10-30 2011-05-05 Centocor Ortho Biotech Inc. Il-17a antagonists
AR080155A1 (es) * 2010-02-10 2012-03-14 Immunogen Inc Anticuerpos anti-cd20 y su utilizacion
CA2789629A1 (en) * 2010-02-10 2011-08-18 Immunogen, Inc. Cd20 antibodies and uses thereof
GB201011771D0 (en) * 2010-07-13 2010-08-25 Bioinvent Int Ab Biological material and particular uses thereof
GB2495113A (en) 2011-09-29 2013-04-03 Bioinvent Int Ab Anti-ICAM-1 antibody for treating multiple-myeloma-related disorders
SG10201603411WA (en) 2011-10-28 2016-07-28 Teva Pharmaceuticals Australia Pty Ltd Polypeptide constructs and uses thereof
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
CN105658217B (zh) 2013-04-29 2021-03-19 约翰霍普金斯大学 经由自体干细胞动员的创伤愈合
CA2909952C (en) 2013-04-29 2021-10-12 Teva Pharmaceuticals Australia Pty Ltd. Anti-cd38 antibodies and fusions to attenuated interferon alpha-2b
UA119352C2 (uk) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
WO2015197639A1 (en) * 2014-06-23 2015-12-30 Vib Vzw Tissue-specific cell depletion with two chimeric proteins
JP6730271B2 (ja) 2014-10-29 2020-07-29 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド インターフェロンα２Ｂバリアント
US9795624B2 (en) 2015-05-04 2017-10-24 Research Foundation Of The City University Of New York Cationic polymers as co-drugs for chemotherapeutic agents
CA2991655A1 (en) 2015-07-10 2017-01-19 Peptinovo Biopharma, Llc Formulations for improving the efficacy of hydrophobic drugs
US11260132B2 (en) 2017-03-16 2022-03-01 Children's Medical Center Corporation Engineered liposomes as cancer-targeted therapeutics
CN107375940B (zh) * 2017-07-18 2020-11-03 福州大学 以粘附因子icam-1为靶点的纳米药物制备及其应用
KR20230059469A (ko) * 2021-10-26 2023-05-03 재단법인 아산사회복지재단 암 생존자 유래 항체 및 이의 용도

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
ES2064327T3 (es) 1987-11-02 1995-02-01 Baylor College Medicine Uso de icam-1 o de sus derivados funcionales para el tratamiento de una inflamacion no especifica.
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DK0387701T3 (da) 1989-03-09 1992-12-07 Boehringer Ingelheim Pharma Anvendelse af intercellulære adhæsionsmolekyler samt deres bindende ligander ved behandling af astma
US5643872A (en) 1989-10-23 1997-07-01 Smithkline Beecham Corporation Cyclic anti-aggregatory peptides
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US6008058A (en) 1993-06-18 1999-12-28 University Of Louisville Cyclic peptide mixtures via side chain or backbone attachment and solid phase synthesis
US5695760A (en) * 1995-04-24 1997-12-09 Boehringer Inglehiem Pharmaceuticals, Inc. Modified anti-ICAM-1 antibodies and their use in the treatment of inflammation
GB9701425D0 (en) 1997-01-24 1997-03-12 Bioinvent Int Ab A method for in vitro molecular evolution of protein function
US6306393B1 (en) 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
AU5588099A (en) * 1998-08-28 2000-03-21 Dendreon Corporation Selective apoptosis of neoplastic cells by an hla-dr specific monoclonal antibody
US20030035798A1 (en) 2000-08-16 2003-02-20 Fang Fang Humanized antibodies
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
US20040110226A1 (en) 2002-03-01 2004-06-10 Xencor Antibody optimization
GB2392723B (en) 2002-09-04 2005-01-12 Bioinvent Int Ab Screening methods
US20060264380A1 (en) 2003-07-21 2006-11-23 Mats Hellstrom Compounds and Methods for Promoting Angiogenesis
EP1671129A1 (en) 2003-07-21 2006-06-21 Angiogenetics Sweden AB Compounds and methods for promoting angiogenesis by using a gamma-secretase inhibitor or inhibiting the gamma-secretase pathway
EP1711527A4 (en) * 2003-12-15 2008-09-03 Dendreon Corp HLA-DR SPECIFIC ANTIBODIES, COMPOSITIONS AND METHODS
WO2005086568A2 (en) 2004-01-26 2005-09-22 Morphosys Ag Anti-icam-1 human antibodies and uses thereof
GB0525214D0 (en) 2005-12-12 2006-01-18 Bioinvent Int Ab Biological materials and uses thereof
CN102099684A (zh) 2008-02-29 2011-06-15 国立大学法人信州大学 前哨淋巴结内转移癌细胞检测试剂盒
GB0903151D0 (en) 2009-02-25 2009-04-08 Bioinvent Int Ab Antibody uses and methods
GB201011771D0 (en) 2010-07-13 2010-08-25 Bioinvent Int Ab Biological material and particular uses thereof
GB2495113A (en) 2011-09-29 2013-04-03 Bioinvent Int Ab Anti-ICAM-1 antibody for treating multiple-myeloma-related disorders
GB201300346D0 (en) 2013-01-09 2013-02-20 Biolnvent Internat Ab BiologIcal materials and uses thereof

Also Published As

Publication number Publication date
PL1960432T3 (pl) 2016-10-31
JP2009518052A (ja) 2009-05-07
ES2577290T3 (es) 2016-07-14
WO2007068485A3 (en) 2007-10-04
SI1960432T1 (sl) 2016-08-31
AU2006326267A1 (en) 2007-06-21
AU2006326267B2 (en) 2012-07-05
DK1960432T3 (en) 2016-06-20
ZA200804864B (en) 2009-09-30
CN102517252A (zh) 2012-06-27
NZ569038A (en) 2011-11-25
RU2008128471A (ru) 2010-01-20
JP2016039824A (ja) 2016-03-24
US20140314793A1 (en) 2014-10-23
IL191868A (en) 2016-12-29
EP1960432A2 (en) 2008-08-27
KR101446508B1 (ko) 2014-10-16
US9803013B2 (en) 2017-10-31
KR20140031402A (ko) 2014-03-12
RU2432363C9 (ru) 2014-04-27
US7943744B2 (en) 2011-05-17
MY147438A (en) 2012-12-14
EP2468775A1 (en) 2012-06-27
CA2632983A1 (en) 2007-06-21
IL191868A0 (en) 2008-12-29
NO341192B1 (no) 2017-09-11
US20090087427A1 (en) 2009-04-02
EP1960432B1 (en) 2016-04-06
US20110262461A1 (en) 2011-10-27
HUE028363T2 (en) 2016-12-28
KR20150023914A (ko) 2015-03-05
HK1121767A1 (zh) 2009-04-30
PT1960432T (pt) 2016-07-07
CN101360760A (zh) 2009-02-04
KR20080090393A (ko) 2008-10-08
UA100664C2 (uk) 2013-01-25
CA2632983C (en) 2016-11-22
RU2432363C2 (ru) 2011-10-27
CN101360760B (zh) 2012-07-04
JP2013005815A (ja) 2013-01-10
NZ595644A (en) 2013-02-22
BRPI0619741A2 (pt) 2011-10-11
GB0525214D0 (en) 2006-01-18
US8758749B2 (en) 2014-06-24
JP5247463B2 (ja) 2013-07-24
WO2007068485A2 (en) 2007-06-21

Similar Documents

Publication Publication Date Title
NO20082524L (no) Biologisk materiale og anvendelse av samme
CU23809A3 (es) Anticuerpo específico prlr
NO20083891L (no) Anti-5T4 antistoffer og anvendelser derav
BRPI0821447A2 (pt) Anticorpo de alvejamento engenheirado, composição farmacêutica, hibridoma, ensaio com base em anticorpo, polipeptídeo isolado, e, método para ligação homogênea
NO20083127L (no) Fremgangsmater og preparater for malretting av polyubiquitin
CL2008003561A1 (es) Construccion de union a il - 13 que comprende a lo menos un dominio simple (dab) de anticuerpo injertado en un anticuerpo monoclonal ( mabdab); polinucleotido y celula huesped; procedimiento para preparar la construccion; composicion farmaceutica que la comprende y uso para tratar cancer o enfermedades inflamatorias.
BRPI0818437A2 (pt) Anticorpo ou fragmento funcional do anticorpo, composição farmacêutica, uso de pelo menosum dos anticorpos ou fragmentos funcionais dos anticorpos, e, hibridoma
BRPI0820270A2 (pt) Anticorpo monoclonal, vetor de expressão, célula, conjugado molecular, composição, uso da composição, método para detectar a presença ou ausência de dec-205 em uma amostra biológica, e, uso de um conjugado molecular.
ECSP088220A (es) Uso de dosis única de moléculas de unión específica cd20
AR057807A1 (es) Formulaciones de anticuerpo anti-cd3
BRPI0812400A2 (pt) Unidade, hibridoma, composição farmacêutica, método para identificar uma unidade, anticorpo isolado a uma unidade de ligação de antígeno do mesmo, molécula peptídica, e, uso da unidade.
EA200702278A1 (ru) Антитела, специфичные в отношении tgf-бета 1
BRPI0808655A2 (pt) anticorpos monoclonais de he4 e métodos para a sua utilização.
DE602006016344D1 (de) Für das fibroblastenaktivierungsprotein spezifische antikörpermoleküle und immunkonjugate, die diese enthalten
ATE505544T1 (de) Monoklonale antikörper und einzelkettenantikörper fragments gegen das zelloberflächen prostataspezifische membranantigen
SV2007002227A (es) Anticuerpos anti-5t4 humanizados y conjugados anticuerpo anti-5t4/calicheamicina ref. 040000-0317637
NO20082658L (no) Fremgangsmåte for behandling av leddskade
BRPI0821375B8 (pt) anticorpos biespecíficos, bivalentes, processo para a preparação destes e composição farmacêutica dos mesmos
DK1742966T3 (da) Antistoffer og molekyler afledt deraf som binder til STEAP-1 proteiner
AR067199A1 (es) Proteinas de union a antigenos que se unen a par-2
NO20083397L (no) Anti-EphB4-antistoffer og fremgangsmater for anvendelse av disse
EA200901421A1 (ru) Антитела к il-25
EA200801174A1 (ru) Антитела-миметики glp-2, полипептиды, композиции, способы и применения
DK1758610T3 (da) Fremgangsmåder til behandling af cancer ved hjælp af IL-21 og monoklonal antistofterapi
BRPI0915667A2 (pt) ligante, fragmentos scfv e fab, anticorpo, composição farmacêutica, ácido nucleico, molécula de ácido nucleico, vetor, célula hospedeira, método para produção do ligante, método de tratamento, antiligante, método de detecção do antiligante em uma amostra biológica, kit de imunoesaio para detecção do antiligante, uso do kit de imunoensaio

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees